Schrodinger (SDGR) vs Sarepta Therapeutics (SRPT)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Schrodinger (SDGR) has outperformed Sarepta Therapeutics (SRPT) over the past year, gaining 27.4% versus a loss of 22.1%. Over five years, SDGR leads with a -52.3% price change compared with -78.4% for SRPT. Schrodinger is the larger company by market cap ($1.97 billion vs $1.92 billion), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | SDGR | SRPT |
|---|---|---|
| Share price | $26.39 | $18.21 |
| Market cap | $1.97B | $1.92B |
| 1-day change | -3.30% | +4.06% |
| YTD return | +47.60% | -15.38% |
| 1-year return | +27.36% | -22.11% |
| 5-year return | -52.33% | -78.37% |
| Forward P/E | — | 7.55 |
| EPS (TTM) | $-0.74 | $-1.57 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $33.78 | $24.68 |
| 52-week low | $10.95 | $14.68 |
| Distance from 52-week high | -21.88% | -26.22% |
| Analyst consensus | none | hold |
| Avg. price target upside | -18.79% | +19.33% |
| Average volume | 1.74M | 2.99M |
| Shares outstanding | 65.64M | 105.63M |
| Employees | 850 | 835 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- SDGR has outperformed SRPT by 49.5 percentage points over the past year.
About Schrodinger
SDGR stock →Schrödinger, Inc., together with its subsidiaries, develops physics-based computational platform that enables discovery of novel molecules for drug development and materials applications in the United States, the Asia-Pacific, Europe, Middle East, Africa, and internationally. The company operates in two segments, Software and Drug Discovery.
Health Care · Biotechnology: Pharmaceutical Preparations · 850 employees
About Sarepta Therapeutics
SRPT stock →Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, siRNA platform, gene therapy, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 45 skipping; and ELEVIDYS, an AAV-based gene therapy, which is contraindicated in patients with any deletion in exon 8 and/or exon 9 in the Duchenne gene.
Health Care · Biotechnology: Pharmaceutical Preparations · 835 employees
SDGR vs SRPT FAQ
Which is bigger, Schrodinger or Sarepta Therapeutics?
Schrodinger (SDGR) is larger, with a market capitalization of $1.97B compared with $1.92B for Sarepta Therapeutics (SRPT).
Which stock has performed better over the past year, SDGR or SRPT?
SDGR returned +27.36% over the past 12 months, compared with -22.11% for SRPT (price return, excluding dividends). Past performance does not predict future results.
Are Schrodinger and Sarepta Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.